Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 6/20 | 0.64 |
| ▸ | CA2 | P00918 | 12/20 | 0.47 |
| ▸ | CA1 | P00915 | 11/20 | 0.47 |
| ▸ | CA9 | Q16790 | 7/20 | 0.47 |
| ▸ | CA12 | O43570 | 5/20 | 0.47 |
| ▸ | CA6 | P23280 | 3/20 | 0.46 |
| ▸ | CA7 | P43166 | 3/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | CA5A | P35218 | 2/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30307782 | 1.00 | PTGES2 (0.64) | PTGES2CA2CA1CA9CA12 | |
| Hydrochloric Acid SCHEMBL9955460 | 0.98 | PTGES2 (0.62) | PTGES2CA2CA1CA9CA12 | |
| Bromide SCHEMBL14247186 | 0.98 | PTGES2 (0.62) | PTGES2CA2CA1CA9CA12 | |
| Hydrochloric Acid SCHEMBL29969652 | 0.98 | PTGES2 (0.62) | PTGES2CA2CA1CA9CA12 | |
| Formic Acid SCHEMBL14247387 | 0.90 | PTGES2 (0.55) | PTGES2CA2CA1CA9CA12 | |
| SCHEMBL789039 | 0.90 | PTGES2 (0.59) | PTGES2CA2CA1CA9CA12 | |
| Trifluoroacetic Acid SCHEMBL25391051 | 0.86 | PTGES2 (0.51) | PTGES2CA2CA1CA9CA12 | |
| SCHEMBL18668386 | 0.82 | PTGES2 (0.48) | PTGES2CA2CA1CA9CA12 | |
| SCHEMBL778219 | 0.81 | AKR1B1 (0.56) | PTGES2AKR1B1 | |
| SCHEMBL29860559 | 0.81 | AKR1B1 (0.56) | PTGES2AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 283 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331026-B2 | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | claimed |
| WO-2024115549-A1 | ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-06 | — | — | WO | claimed |
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-09-28 | — | — | US | claimed |
| EP-3923911-B1 | USE OF TOPICAL BRAF INHIBITOR COMPOSITIONS FOR TREATMENT OF RADIATION DERMATITIS | LUTRIS PHARMA LTD (IL) | 2023-07-12 | — | — | EP | claimed |
| EP-3426254-B1 | USE OF BRAF INHIBITORS FOR TREATING CUTANEOUS REACTIONS | LUTRIS PHARMA LTD (IL) | 2023-06-07 | — | — | EP | claimed |
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | claimed |
| US-20220153734-A1 | Pyrazolopyridine Compounds For IRE1 Inhibition | Optikira, LLC | 2022-05-19 | — | — | US | claimed |
| US-20210171544-A1 | Heterocyclic Compound as a Protein Kinase Inhibitor | HK INNO.N CORPORATION (KR) | 2021-06-10 | — | — | US | claimed |
| EP-3664849-A1 | USE OF BRAF INHIBITORS FOR TREATING CUTANEOUS REACTIONS CAUSED BY TREATMENT WITH A MEK INHIBITOR | Memorial Sloan-Kettering Cancer Center (US) | 2020-06-17 | — | — | EP | claimed |
| US-20200163967-A1 | USE OF BRAF INHIBITORS FOR TREATING CUTANEOUS REACTIONS CAUSED BY TREATMENT WITH A MEK INHIBITOR | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-05-28 | — | — | US | claimed |
| EP-1879877-A2 | ANTIMICROBIAL AGENTS | Ranbaxy Laboratories Limited (IN) | 2008-01-23 | — | — | EP | claimed |
| EP-1841754-A1 | N-[(4,5-DIPHENYL-2-THIENYL)METHYL]SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THEIR THERAPEUTIC APPLICATION | Sanofi-Aventis (FR) | 2007-10-10 | — | — | EP | claimed |
| CN-1968956-A | Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2007-05-23 | — | — | CN | claimed |
| CN-1946391-A | Combinations comprising alpha-2-delta ligands | PFIZER PROD INC (US) | 2007-04-11 | — | — | CN | claimed |
| WO-2006126939-A1 | NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | claimed |
| WO-2006117762-A2 | ANTIMICROBIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-09 | — | — | WO | claimed |
| WO-2006077320-A1 | N-[(4,5-DIPHENYL-2-THIENYL)METHYL]SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2006-07-27 | — | — | WO | claimed |
| EP-1054886-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-11-29 | — | — | EP | claimed |
| CN-1247537-A | Sulfonamide compounds having 5-HT receptor activity | KNOLL AG (DE) | 2000-03-15 | — | — | CN | claimed |
| WO-1999040088-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1999-08-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171544-A1 | Heterocyclic Compound as a Protein Kinase Inhibitor | MAP3K20, MAP3K15, MAP3K1 | PTGES2 3167/4885CA2 1173/4885CA1 1951/4885 |
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | CDK2, CCNK, CCNI | PTGES2 1240/4885CA2 2801/4885CA1 3540/4885 |
| US-12331026-B2 | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors | CDK2, CCNK, CCNI | PTGES2 1240/4885CA2 2801/4885CA1 3540/4885 |
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | PTGES2 3167/4885CA2 1173/4885CA1 1951/4885 |
| US-20220153734-A1 | Pyrazolopyridine Compounds For IRE1 Inhibition | XBP1, ERN1, ERN2 | PTGES2 2154/4885CA2 4235/4885CA1 4705/4885 |
| US-20200163967-A1 | USE OF BRAF INHIBITORS FOR TREATING CUTANEOUS REACTIONS CAUSED BY TREATMENT WITH A MEK INHIBITOR | BRAF, NRAS, RAF1 | PTGES2 1536/4885CA2 2088/4885CA1 3944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.